Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer
Antioxidants · 13.04.2023 · 12 (4) · 926
DOI: 10.3390/antiox12040926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 13.04.2023. Verfasst von Sara Moreno-SanJuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cytometry and Microscopy Research Service, Biosanitary Research Institute of Granada (ibs.GRANADA), 18012 Granada, Spain. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Instituto de Salud Carlos III- FEDER, Junta de Andalucía.
Abstract (Originalsprache)
The potential use of agomelatine as an alternative treatment for colorectal cancer is evaluated in this work. The effect of agomelatine was studied in an in vitro model using two cell lines with different p53 statuses (HCT-116, wild-type p53, and HCT-116 p53 null) and an in vivo xenograft model. The inhibitory effects of agomelatine and melatonin were stronger in the cells harboring the wild-type p53, although in both cell lines, the effect of agomelatine was greater than that of the melatonin. In vivo, only agomelatine was able to reduce the volumes of tumors generated by the HCT-116-p53-null cells. Both treatments induced changes in the rhythmicity of the circadian-clock genes in vitro, albeit with some differences. Agomelatine and melatonin regulated the rhythmicity of Per1-3, Cry1, Sirt1, and Prx1 in the HCT-116 cells. In these cells, agomelatine also regulated Bmal1 and Nr1d2, while melatonin changed the rhythmicity of Clock. In the HCT-116-p53-null cells, agomelatine regulated Per1-3, Cry1, Clock, Nr1d2, Sirt1, and Prx1; however, melatonin only induced changes in Clock, Bmal1, and Sirt1. The differences found in the regulation of the clock genes may explain the greater oncostatic effect of agomelatine in CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cytometry and Microscopy Research Service, Biosanitary Research Institute of Granada (ibs.GRANADA), 18012 Granada, Spain.
- Biosanitary Research Institute of Granada (ibs.GRANADA), 18012 Granada, Spain.
- Department of Pharmacy, University of Granada, 18011 Granada, Spain.
- Fundamental Biology Service, Scientific Instrument Center, University of Granada, 18071 Granada, Spain.
- Department of Statistics and Operations Research, University of Granada, 18071 Granada, Spain.
- Clinical Management Unit of Microbiology, San Cecilio University Hospital, 18006 Granada, Spain.
ORCID-Profile: Jose D Puentes-Pardo, Julia Escudero-Feliu, Javier Arnedo, Josefa León
Förderung
- Instituto de Salud Carlos III
- Instituto de Salud Carlos III- FEDER
- Junta de Andalucía
- Andalusian Health Service
- Ministerio de Universidades (Spain)
Zitieren
APA
Moreno-SanJuan, S., Puentes-Pardo, J. D., Casado, J., Escudero-Feliu, J., Khaldy, H., Arnedo, J., Carazo, Á., & León, J. (2023). Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer. Antioxidants, 12(4), 926. https://doi.org/10.3390/antiox12040926
Vancouver
Moreno-SanJuan S, Puentes-Pardo JD, Casado J, Escudero-Feliu J, Khaldy H, Arnedo J, et al. Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer. Antioxidants. 2023;12(4):926. doi:10.3390/antiox12040926
BibTeX
@article{MorenoSanJuan2023,
author = {Moreno-SanJuan, Sara and Puentes-Pardo, Jose D and Casado, Jorge and Escudero-Feliu, Julia and Khaldy, Huda and Arnedo, Javier and Carazo, Ángel and León, Josefa},
title = {Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer},
journal = {Antioxidants},
year = {2023},
volume = {12},
number = {4},
pages = {926},
doi = {10.3390/antiox12040926}
}
EUVIMED